Antigen Level Articles & Analysis
13 news found
The research demonstrates a clinical sensitivity at a landmark of 61.1% and a robust surveillance performance with longitudinal sensitivity of 83.3% and specificity of 89.5% across stage II/III CRC patients. xM MRD results predict disease-free survival (DFS) nearly 5 times stronger compared to standard of care carcinoembryonic antigen (CEA) level (Adj. Hazard ...
ByTempus
BCR is defined as rising prostate-specific antigen (PSA) levels with a doubling time of after primary treatment (surgery or radiotherapy).1,2 Darolutamide is already approved under the brand name NubeqaTM for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease as well ...
ByBayer AG
In addition, a study to explore the potential of darolutamide in the early setting for patients who have experienced a rise in their prostate specific antigen (PSA) levels following surgery or radiation, is also planned. ...
ByBayer AG
In addition, a study to explore the potential of darolutamide in the early setting for patients who have experienced a rise in their prostate specific antigen (PSA) levels following surgery or radiation, is also planned. ...
ByBayer AG
In addition, a study to explore the potential of darolutamide in the early setting for patients who have experienced a rise in their prostate specific antigen (PSA) levels following surgery or radiation, is also planned. ...
ByBayer AG
In addition, a study to explore the potential of darolutamide in the early setting for patients who have experienced a rise in their prostate specific antigen (PSA) levels following surgery or radiation, is also planned. ...
ByBayer AG
In addition, a study to explore the potential of darolutamide in the early setting for patients who have experienced a rise in their prostate specific antigen (PSA) levels following surgery or radiation, is also planned. ...
ByBayer AG
NOTE: Axumin® (fluciclovine F 18) injection is FDA-approved for PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. HIGHLIGHTED SCIENTIFIC PRESENTATION Friday, December 3, 2021 SUO presentations are available at designated times for the meeting in Orlando and ...
NOTE: Axumin® (fluciclovine F 18) injection is FDA-approved for PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. Presentations noted by "*" discuss results of investigational studies of an approved product that is not approved by the FDA for the specific use ...
In addition, a study to explore the potential of darolutamide in the early setting for patients who have been treated with surgery or radiation and now see a rise in their prostate specific antigen (PSA) levels is also planned. About Nubeqa (darolutamide) Darolutamide is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to ...
ByBayer AG
Interim data from 27 patients, who had completed 3 months in the HBV002 study in chronic Hepatitis B (CHB) patients, demonstrated noted changes in surface antigen (HBsAg) levels, especially in the group receiving low-dose nivolumab with the heterologous boost (VTP-300). ...
Axumin, a novel amino acid-based radiopharmaceutical, is FDA-approved for PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. The secondary analysis is based on the Axumin LOCATE and FALCON trials, which have safety profiles consistent with that described in the ...
NanoPin is bringing to market a diagnostic platform that sensitively detects TB antigen levels present in patient blood samples in a matter of hours. ...